BR0311772A - inibidores da atividade do gene inflamatório e da biossìntese do colesterol - Google Patents

inibidores da atividade do gene inflamatório e da biossìntese do colesterol

Info

Publication number
BR0311772A
BR0311772A BRPI0311772-3A BR0311772A BR0311772A BR 0311772 A BR0311772 A BR 0311772A BR 0311772 A BR0311772 A BR 0311772A BR 0311772 A BR0311772 A BR 0311772A
Authority
BR
Brazil
Prior art keywords
inhibitors
gene activity
cholesterol biosynthesis
inflammatory gene
methods
Prior art date
Application number
BRPI0311772-3A
Other languages
English (en)
Inventor
Mark J Evans
Douglas C Harnish
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority claimed from PCT/US2003/018651 external-priority patent/WO2003106632A2/en
Publication of BR0311772A publication Critical patent/BR0311772A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

INIBIDORES DA ATIVIDADE DO GENE INFLAMATóRIO E DA BIOSSìNTESE DO COLESTEROL. A presente invenção refere-se a métodos de identificação de agentes eficazes como inibidores da proteína heterodímera curta (SHP) e do receptor de famesóide X (FXR) e de promotores, linhas celulares e vetores usados nos ditos métodos. Os métodos de preparação e utilização dos agentes eficazes como inibidores da proteína heterodímera curta (SHP), incluem os métodos de uso da mesma para prevenção e/ou tratamento de um condição associado a uma atividade de gene inflamatório e/ou biossíntese de colesterol em um sujeito. Agentes eficazes, como inibidores da proteína heterodímeta curta (SHP) e do receptor de farnesóide X (FXR) e composições compreendendo os mesmos, incluem as composicoes eficazes usadas na redução da atividade do gene inflamatório e/ou da biossíntese do colesterol em um sujeito.
BRPI0311772-3A 2002-06-13 2003-06-13 inibidores da atividade do gene inflamatório e da biossìntese do colesterol BR0311772A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38791502P 2002-06-13 2002-06-13
US47018803P 2003-05-14 2003-05-14
PCT/US2003/018651 WO2003106632A2 (en) 2002-06-13 2003-06-13 Inhibitors of inflammatory gene activity and cholesterol biosynthesis

Publications (1)

Publication Number Publication Date
BR0311772A true BR0311772A (pt) 2007-05-08

Family

ID=34425702

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311772-3A BR0311772A (pt) 2002-06-13 2003-06-13 inibidores da atividade do gene inflamatório e da biossìntese do colesterol

Country Status (10)

Country Link
US (1) US20050221328A1 (pt)
EP (1) EP1560925A4 (pt)
JP (1) JP2006505249A (pt)
KR (1) KR20050010916A (pt)
CN (1) CN1675376A (pt)
BR (1) BR0311772A (pt)
CA (1) CA2489594A1 (pt)
EA (1) EA200500012A1 (pt)
MX (1) MXPA04012560A (pt)
NO (1) NO20045536L (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137516A1 (en) * 2007-11-05 2009-05-28 Wyeth Compositions and methods of treating dyslipidemia
WO2009141926A1 (ja) * 2008-05-23 2009-11-26 国立大学法人東京大学 糖代謝・脂質代謝に作用する化合物の取得方法
RU2705249C2 (ru) * 2013-07-12 2019-11-06 Дзе Чилдрен'З Хоспитал Оф Филадельфия Вектор aav и анализ на нейтрализующие антитела против aav (аденоассоциированного вируса)
US10301268B2 (en) * 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US20230174951A1 (en) * 2020-04-26 2023-06-08 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Phenol-rich grapes
CN114022409B (zh) * 2021-09-30 2023-04-18 电子科技大学 基于深度学习的包覆药表面缺陷检测算法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753431A (en) * 1993-10-13 1998-05-19 Northeastern Ohio University Cholesterol 7 α-hydroxdylase gene regulatory elements and transcription factors
US5728548A (en) * 1995-06-29 1998-03-17 Genetics Institute, Inc. Retinoid receptor-1 (RR1) and DNA encoding RR1
US6316181B1 (en) * 1998-04-24 2001-11-13 Virginia Commonwealth University Establishment of cell lines with persistent expression of a green fluorescent protein (GFP) using a pIRES/EGFP DNA vector construct
US20030083484A1 (en) * 2001-07-31 2003-05-01 Crooke Rosanne M. Antisense modulation of short heterodimer partner-1 expression
AU4948800A (en) * 1999-05-24 2000-12-12 Sankyo Company Limited Method for searching physiologically active substance
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001079224A2 (en) * 2000-04-12 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the cyp8b1 gene
AU2001280974A1 (en) * 2000-07-31 2002-02-13 Glaxo Group Limited Identification of new therapeutic targets for modulating bile acid synthesis
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders

Also Published As

Publication number Publication date
NO20045536L (no) 2005-02-28
CA2489594A1 (en) 2003-12-24
EP1560925A2 (en) 2005-08-10
US20050221328A1 (en) 2005-10-06
CN1675376A (zh) 2005-09-28
KR20050010916A (ko) 2005-01-28
JP2006505249A (ja) 2006-02-16
EP1560925A4 (en) 2006-10-25
MXPA04012560A (es) 2005-10-19
EA200500012A1 (ru) 2006-04-28

Similar Documents

Publication Publication Date Title
Waddell et al. Dlk1 is necessary for proper skeletal muscle development and regeneration
CL2020000991A1 (es) Proteínas trispecíficas y métodos de uso.
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BR112012027765A2 (pt) métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
BRPI0511133A (pt) uso de galacto-oligossacarìdeos e polifrutose
BRPI0409128A (pt) uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
BRPI0517286A (pt) modulação de rnai de rsv, piv e outras viroses respiratórias e empregos desta
BRPI0512674A (pt) compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
NO20065442L (no) Amidoforbindelser og deres anvendelse som legemidler
Gao et al. TOB1 deficiency enhances the effect of bone marrow-derived mesenchymal stem cells on tendon-bone healing in a rat rotator cuff repair model
BR112013001270A2 (pt) celulossoma artificial e o uso do mesmo para a degradação enzimática de substratos resilentes.
BRPI0721137B8 (pt) compostos para modulação de atividade de c-fms e/ou kit, composição, kit e uso dos referidos compostos.
BR9916894A (pt) ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
BRPI0507626A (pt) compostos e composiçoes como moduladores de lxr
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
CL2007001590A1 (es) Compuestos derivados de tioxantina; inhibidores de la enzima mieloperoxidasa (mpo); composicion farmaceutica; y su uso para tratar desordenes inflamatorios como esclerosis multiple, mal de parkinson, ateroesclerosis, enfermedad pulmonar obstructiva cronica (copd), bronquitis infecciosa y eosinofilica y fibrosis quistica.
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
Furuta et al. High molecular weight hyaluronic acid regulates MMP13 expression in chondrocytes via DUSP10/MKP5
Rhee et al. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-κB in response to CpG-oligodeoxynucleotides in RAW 264.7 cells
BRPI0607504A2 (pt) população de suìnos que possui baixos nìveis de retrovìrus endógenos suìnos e usos dos mesmos
BR0311772A (pt) inibidores da atividade do gene inflamatório e da biossìntese do colesterol
BR0314053A (pt) Pirazolopiridinas e métodos de obtenção e uso das mesmas
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
Hu et al. TGF-β induces up-regulation of chondroitin sulfate synthase 1 (CHSY1) in nucleus pulposus cells through MAPK signaling

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.